Stay updated on Nivolumab Combo in Relapsed/Refractory HL Clinical Trial
Sign up to get notified when there's something new on the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page.
Latest updates to the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page
- Check5 days agoChange DetectedA consolidated Locations section was added and organized to list study sites in California, Connecticut, Texas, and Washington, with related per-location entries updated accordingly.SummaryDifference0.4%
- Check12 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedPublications section wording now states that publications are automatically filled from PubMed, and the revision label was updated from v3.2.0 to v3.3.2.SummaryDifference0.1%
- Check41 days agoChange DetectedThe page no longer shows the government funding lapse notice regarding NIH operations. The study details and participation information remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check55 days agoChange DetectedNo additions or deletions detected; the page content remains the same study record with only routine updates such as timestamps or formatting changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%
- Check84 days agoChange DetectedUpdated version to v3.2.0 and added a government operating-status notice for NIH Clinical Center, directing users to cc.nih.gov and opm.gov.SummaryDifference2%
- Check91 days agoChange DetectedUpdated version from v3.0.2 to v3.1.0, indicating a new release. No other content changes were detected.SummaryDifference0.0%
Stay in the know with updates to Nivolumab Combo in Relapsed/Refractory HL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab Combo in Relapsed/Refractory HL Clinical Trial page.